TGFB1 and head and neck squamous cell carcinoma: Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, achieved promising clinical outcomes in a phase I trial in advanced HNSCC patients with a manageable safety profile.